Hypersensitivity or Development of Antibodies to Asparaginase Does Not Impact Treatment Outcome of Childhood Acute Lymphoblastic Leukemia
Michael H. Woo(St. Jude Children's Research Hospital), Mary V. Relling(St. Jude Children's Research Hospital), William E. Evans(St. Jude Children's Research Hospital), Jeffrey E. Rubnitz(St. Jude Children's Research Hospital), Raul C. Ribeiro(St. Jude Children's Research Hospital), Bo Wang(State Key Laboratory of Oncogene and Related Genes), Patricia Harrison(University of Pittsburgh), John T. Sandlund(St. Jude Children's Research Hospital), Lawrence J. Hak(St. Jude Children's Research Hospital), Gaston K. Rivera(St. Jude Children's Research Hospital), Michael C. Storm(St. Jude Children's Research Hospital), Ching‐Hon Pui(St. Jude Children's Research Hospital)
Cited by 183
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Treatment of Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2006|2k
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling
|Cancer Cell|2002|1.9k
Acute lymphoblastic leukaemia
|The Lancet|2008|1.6k